Overstock Deal Epz-5676 (pinometostat) With A 65% Price Cut [PCFV1Mke]

Overstock Deal Epz-5676 (pinometostat) With A 65% Price Cut [PCFV1Mke]: A Potent Inhibitor for Histone Methyltransferase

Overstock Deal Epz-5676 (pinometostat) With A 65% Price Cut [PCFV1Mke] is a cutting-edge small molecule inhibitor designed to target histone methyltransferase, a key enzyme in the regulation of gene expression and chromatin structure. This innovative compound exhibits exceptional antineoplastic activity, making it a valuable tool in the fight against cancer. With its ability to specifically block the activity of the histone lysine-methyltransferase DOT1L, EPZ-5676 effectively inhibits the methylation of nucleosomal histone H3 on lysine 79 (H3K79), which is crucial for the function of the mixed lineage leukemia (MLL) fusion protein. This targeted approach offers a promising strategy for treating leukemias and other cancers with MLL fusion proteins.

• Targeted Therapy: Blocks the activity of DOT1L, inhibiting H3K79 methylation and MLL fusion protein function.
• Antineoplastic Activity: Demonstrates potential in treating leukemias and cancers with MLL fusion proteins.

Technical Specifications and Product Details

Overstock Deal Epz-5676 (pinometostat) With A 65% Price Cut [PCFV1Mke] is a solid powder with a chemical formula of C30H42N8O3 and a molecular weight of 562.7. It is highly pure, exceeding 99% by HPLC, ensuring consistent and reliable results. The compound is soluble in DMSO, making it easy to use and handle. With a storage life of up to three years at -20°C or several months at room temperature, EPZ-5676 offers flexibility in research and clinical applications.

• High Purity: >99% by HPLC, ensuring consistent and reliable results.
• Storage Stability: Stable for months at room temperature or years at -20°C.

Applications and Benefits

Overstock Deal Epz-5676 (pinometostat) With A 65% Price Cut [PCFV1Mke] is a versatile tool for researchers and clinicians seeking to understand and treat cancers involving histone methyltransferase activity. Its specific inhibition of DOT1L and MLL fusion proteins makes it particularly valuable in the study of leukemias and other hematological malignancies. By blocking the methylation of H3K79, EPZ-5676 can potentially disrupt the expression of leukemogenic genes, offering a promising approach to cancer therapy. This powerful inhibitor is an essential addition to any laboratory or clinical setting focused on the study and treatment of histone methyltransferase-related diseases.

• Research Tool: Ideal for studying histone methyltransferase activity and its role in cancer development.
• Clinical Application: Offers a targeted therapy approach for leukemias and hematological malignancies.